A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer
A Phase I study of SH003 for evaluate safe dose range in patients with solid cancer.
The first dose group receives SH003 for 3 weeks. If the adverse events occur in less than one in six participants, the dose is escalated.
The second dose group receives SH003 for 3 weeks. If the adverse events occur in less than one in six participants, the dose is escalated.
The third dose group receives SH003 for 3 weeks.
|Study Design:||Intervention Model: Sequential Assignment
Masking: No masking
Primary Purpose: Other
|Official Title:||A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer|
- Adverse events [ Time Frame: 3 weeks ]Grade 3-4 adverse event using CTCAE v4.03
|Anticipated Study Start Date:||March 20, 2017|
|Estimated Study Completion Date:||February 2018|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|
Participant will take SH003 for 3 weeks.
Herbal medicine for cancer treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT03081819
|Contact: Chunhoo Cheon, Doctoremail@example.com|
|Korea, Republic of|
|Ajou University Hospital||Recruiting|
|Suwon, Korea, Republic of, 16499|
|Contact: EUNJIN KWON +82-31-219-6324|